Gilead Sciences (NASDAQ: [[ticker:GILD]]), the world’s largest maker of HIV drugs, said today it has expanded its global access program to offer HIV/AIDS drugs at low prices in poor countries. The Foster City, CA-based company said four Indian partners and the Medicines Patent Pool Foundation will get access to the experimental drug elvitegravir, the experimental “Quad” that combines four antiviral meds into a single daily pill, and an antiretroviral boosting agent. Partners will have the rights to sell generic versions of the new Gilead medicines, if they are approved by regulators, the company said.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
